Drugs / Trifluridine/Tipiracil
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05029882 | Oct 2021 → Nov 2027 expected | colorectal cancer, gastroesophageal adenocarcinoma, non-small cell lung carcinoma | AbbVie | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/Tipiracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05029882 ↗ |
| Route | Oral | “Oral Tablet” NCT05029882 ↗ |